BackTable / Urology / Contributor
Dr. Aditya Bagrodia
Dr. Aditya Bagrodia is an associate professor of urology and genitourinary oncology team leader at UC San Diego Health in California and adjunct professor of urology at UT Southwestern.
Listen to Dr. Aditya Bagrodia on the BackTable Urology Podcast
The BackTable Podcast is a knowledge resource by physicians for physicians. Learn from the experiences and expertise of Dr. Aditya Bagrodia and get practical advice on how to build your practice by listening to the BackTable Urology Podcast.
Reflect on how this Podcast applies to your day-to-day and earn free AMA PRA Category 1 CMEs. Follow the button below to claim your credits on CMEfy.
Stay Up To Date
About Dr. Aditya Bagrodia
Aditya Bagrodia, M.D., is an associate professor of urology and genitourinary oncology team leader at UC San Diego Health in California and adjunct professor of urology at UT Southwestern.
Dr. Bagrodia holds a bachelor of science degree from Rhodes College. While earning a medical degree with highest honors at the University of Tennessee Health Sciences Center, he was awarded a Doris Duke Clinical Research Fellowship at UT Southwestern Medical Center.
After completing his residency in urology at UT Southwestern, he received advanced training in urologic oncology through a fellowship at Memorial Sloan Kettering Cancer Center, where he was awarded a Urology Care Foundation Research Scholars Grant by the American Urological Association.
Dr. Bagrodia’s clinical practice focuses on treating all urologic malignancies, including adrenal, upper tract, renal, bladder, prostate, penile, and testicular cancers. He has expertise in complex multidisciplinary management and minimally invasive approaches to urologic surgery.
Dr. Bagrodia has conducted extensive research in urologic oncology, primarily in biomarker profiles and molecular signatures of urologic tumors as predictors of clinical outcomes. He is funded through competitive grants from the Cancer Prevention and Research Institute of Texas (CPRIT), intramural research grants, and the National Institutes of Health.
Both his clinical practice and research centers on patients with germ cell tumors (most commonly testicular cancer). His laboratory focuses on sequencing efforts to understand tumor evolution and heterogeneity in germ cell tumors and identifying novel biomarkers to recognize occult metastatic disease. The Bagrodia lab also conducts experiments in cell lines, zebrafish germ cell tumor models, and mice to understand the biologic implications of genetic alterations that are seen exclusively among patients with cisplatin-resistance disease. He is actively working on molecular biomarkers to identify minimal residual disease burden. On the clinical side, Dr. Bagrodia is actively involved in understanding and overcoming unique socioepidemiologic considerations that adversely impact oncologic outcomes in patients with germ cell tumors. He is also the principal investigator for several germ cell tumor-directed clinical trials at UT Southwestern (including NCT03426865 and NCT02537548).
Dr. Bagrodia is the principal author or co-author of more than 100 articles in peer-reviewed publications such as Journal of Clinical Oncology, Nature Genetics, European Urology, Journal of Urology, Urologic Oncology, and Urology. He is also a reviewer for many of these publications, as well as for the British Journal of Urology, Journal of Clinical Pathology, and Annals of Surgical Oncology.
Learn more by visiting Dr. Aditya Bagrodia's practice:
Podcasts Featuring Dr. Aditya Bagrodia
In this episode of BackTable Urology, Dr. Aditya Bagrodia speaks with urologist Dr. Anne Schuckman from the University of Southern California about advantages and advice for blue light cystoscopy, a procedure performed to identify bladder tumors during transurethral resection of bladder tumor (TURBT).
Articles Featuring Dr. Aditya Bagrodia
BCG-unresponsive bladder cancer has distinct criteria for diagnosis and management. Official FDA diagnosis requires the development or recurrence of a high-grade bladder tumor after a patient has received adequate BCG therapy. Treatment duration varies based on whether an induction or maintenance course is indicated.
Thank you for listening! If you have a question for Dr. Aditya Bagrodia about a topic discussed on the BackTable Urology Podcast, you can get in touch with this form. Please note that our contributors are not able to respond to every inquiry.
Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.